Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
First in human, open-label, sequential dose escalation and expansion study of oral BAL101553
in adult patients with advanced solid tumors and adult patients with recurrent or progressive
glioblastoma or high-grade glioma.